PT-141 targets sexual desire and the distress caused by losing it. Two 24-week trials studied 1.75 mg subcutaneous bremelanotide in premenopausal women with acquired, generalized HSDD. Rebody offers needle-free nasal spray and troche formats for women choosing the bremelanotide route.
Current Rebody pricing: PT-141 nasal spray is $99.50 for the first month, then $199 per 5 mL bottle. PT-141 troches are $54.50 for the first month, then $109 per 8-count package for 1 mg; $59.50 for the first month, then $119 for 2 mg.
The short answer
PT-141 and bremelanotide refer to the same active. FDA-approved Vyleesi is the specific injection product. In the pivotal trials, bremelanotide improved desire scores and reduced distress related to low desire compared with placebo.
The trials found improved desire and reduced distress. The co-primary satisfying-sexual-event endpoint was similar to placebo, keeping the measured benefit centered on desire and distress.
Who was actually studied
The RECONNECT trials enrolled 1,267 premenopausal women with acquired, generalized HSDD. “Acquired” means desire had declined from a previous level. “Generalized” means the concern was not confined to one partner, one activity, or one situation.
HSDD also requires distress. A woman whose desire is lower than a partner's preference but not distressing to her does not meet that defining feature.
The low desire could not be better explained by another medical or psychiatric condition, relationship problem, or medication or substance effect. That boundary is part of the result, not a footnote.
What the phase 3 trials found
Participants used 1.75 mg subcutaneous bremelanotide as needed for 24 weeks. The trials measured the Female Sexual Function Index desire domain and distress related to low desire.
Bremelanotide produced statistically significant improvements over placebo on desire and distress measures. The satisfying-sexual-event co-primary endpoint did not show a significant treatment difference.
Women in the defined HSDD population reported improved desire and less distress. More sex, relationship quality, orgasm, and lubrication are separate outcomes.
Desire is different from arousal
Desire is interest or motivation. Arousal can be subjective excitement, genital response, or both. Lubrication is one physiological response. Orgasm is a separate event.
These processes can align or split. A woman can want sex and experience dryness. She can have physiological arousal without spontaneous desire. She can experience responsive desire after intimacy begins.
PT-141's pivotal evidence centered on desire and distress. Calling it “female Viagra” blurs desire with blood flow and creates the wrong expectation.
Painful sex starts with the source of pain
Pain, burning, dryness, pelvic-floor tension, genitourinary syndrome of menopause, endometriosis, vulvar conditions, or infection can suppress desire. Those symptoms need their own cause and treatment.
A desire medication targets interest rather than tissue pain. When pain is the first problem named, begin with the cause of that pain.
Likewise, relationship safety, consent, privacy, exhaustion, and trauma cannot be manufactured by melanocortin signaling.
PT-141 works through melanocortin signaling
Bremelanotide acts through melanocortin receptors in the central nervous system. Estrogen and testosterone belong to separate hormonal pathways.
Hormonal changes can still influence desire, sleep, tissue comfort, mood, and energy. Menopause and postpartum periods can combine several of those changes.
When the complaint includes hot flashes, dryness, painful sex, cycle changes, or other hormone-linked symptoms, a bremelanotide-only frame may be too narrow.
That distinction also prevents a common expectation error. A desire response would not prove that estrogen, testosterone, thyroid function, or ovarian biology changed. If the original complaint includes cycle disruption, fertility concerns, hot flashes, vaginal tissue symptoms, or broader energy changes, those outcomes need their own evaluation rather than being judged through one evening's sexual response.
The approved injection
Vyleesi is a 1.75 mg subcutaneous autoinjector used under its FDA label at least 45 minutes before anticipated sexual activity. The label also defines maximum use.
The injection has the strongest evidence because the actual finished product and dose were tested. It also carries injection-site reactions and needle burden.
Do not call a compounded nasal spray or troche generic Vyleesi. Same active does not mean same exposure or outcome evidence.
The nasal route
Rebody's nasal product contains bremelanotide at 10 mg/mL in a refrigerated 5 mL bottle. Nasal wins practical administration because spraying takes seconds.
A small double-blind crossover experiment studied one 20 mg intranasal dose in 18 premenopausal women with female sexual arousal disorder. It did not test the Rebody bottles or pivotal HSDD outcomes.
The pharmacy label supplies pump output, sprays per dose, priming, timing, maximum frequency, and expected uses. Concentration alone cannot answer how to use it.
The troche route
The 1 mg and 2 mg mini troches come in refrigerated 8-count packages and dissolve beneath the tongue or between gum and cheek as directed on the label.
Troche is the practical alternative when nasal use, congestion, or pump technique is unacceptable. No route-specific clinical outcome trial establishes either strength.
Do not copy the injection's 45-minute timing, split a troche without permission, or call sublingual placement completely absorbed.
How quickly does PT-141 work?
For Vyleesi injection, the label says use at least 45 minutes before anticipated activity. Nasal and troche timing comes from their own prescription labels.
Online reports vary from rapid to many hours and often involve different routes, doses, suppliers, populations, and combinations. They cannot establish a reliable timeline.
Administration speed is not clinical onset. Nasal use takes seconds; troche dissolves more slowly. The felt effect may follow a different curve.
How long do effects last?
No single duration can be promised across routes. Blood concentration, physiological response, and subjective desire do not necessarily end at the same time.
Anecdotes claiming effects lasting one or two days are especially difficult to interpret because other medications, expectation, and individual variability matter.
Use the route-specific assessment window when final. Do not repeat a dose because an expected duration or onset from a forum does not match the experience.
Nausea is the main practical side effect
Nausea was the most common adverse reaction in the Vyleesi clinical program and a major reason women ask whether the experience is worth it. The label also reports flushing, headache, vomiting, injection-site reactions, fatigue, dizziness, and nasal symptoms among adverse events.
Do not promise that nasal or troche administration eliminates nausea. Route can change exposure and local effects, but no reliable finished-product comparison establishes a nausea winner.
Persistent vomiting or inability to keep down medication and fluids deserves prompt guidance.
Blood pressure and cardiovascular safety
Bremelanotide can transiently increase blood pressure and reduce heart rate. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease.
The label advises considering cardiovascular risk before treatment. A woman should not use a needle-free route as a way around the active's safety profile.
Seek urgent care for chest pain, fainting, severe shortness of breath, neurological symptoms, or a severe allergic reaction.
Hyperpigmentation, pregnancy, and interactions
Focal hyperpigmentation involving areas such as the face, gums, or breasts has been reported, especially with more frequent use, and may not fully resolve in all cases.
The label advises discontinuing Vyleesi if pregnancy is suspected. Route-specific pregnancy guidance must accompany compounded products.
Bremelanotide can delay gastric emptying and alter absorption of oral medications. It can reduce exposure to oral naltrexone. These interaction questions remain relevant even when administration is nasal or buccal.
Reviews and first-use stories
Online experiences are useful for discovering friction: nausea, uncertain timing, variable response, flushing, congestion, taste, and anxiety about planning. They are poor evidence for dose or expected results.
Many reports come from men, research products, injections reconstituted at home, or unknown-strength sprays. Those are not interchangeable with a prescribed Rebody route.
A first use can fail because the symptom was not HSDD, timing was wrong, administration failed, or the person simply did not respond. Do not self-escalate.
Before a first use, decide what will count as meaningful: more spontaneous interest, easier transition into responsive desire, less distress about absent interest, or no change. Record timing, route technique, nausea, flushing, other medication use, food and alcohol, and the setting. This is more informative than labeling an evening a success or failure based only on whether intercourse or orgasm happened.
Storage and travel
Rebody's nasal and troche products are refrigerated. Keep them labeled, protected from freezing, and secured from children or accidental household use.
The bottle needs leak and cap protection. Troches need moisture and crush protection. Ask about permitted time outside refrigeration before travel.
If a shipment arrives warm or damaged, record timing and package condition. Do not judge quality by bottle clarity, troche hardness, or temperature to the touch alone.
Cost, count, and access
Rebody's PT-141 nasal spray is $99.50 first month, then $199 per 5 mL bottle. PT-141 troches are $54.50 first month, then $109 per 8-count package for 1 mg; $59.50 first month, then $119 for 2 mg. The label determines prescribed uses; a 5 mL bottle or 8-count package does not automatically equal a month.
Vyleesi pricing and insurance coverage change and should be checked through current authoritative sources. A brand copay and a compounded package price are not directly comparable without expected uses.
Compare route, package price, prescribed uses, refrigeration, shipping, and refill timing.
The assessment period matters to value as much as package price. A woman should know how many properly timed uses are expected before deciding that the product is or is not useful, what side effects should end the trial sooner, and whether a refill occurs automatically. Without that information, a cheap first package can become an expensive sequence of poorly timed attempts, while a higher package price can look misleadingly costly without its use count.
Questions women ask
Does PT-141 make women instantly aroused?
The pivotal evidence measured desire and distress across 24 weeks. A route-specific prescription supplies the timing window for an individual use.
Does it help orgasm?
The phase 3 evidence centers on desire and distress. Orgasm is a separate sexual outcome with additional physical and contextual drivers.
Does it work after menopause?
Vyleesi's cited indication and pivotal trials are in premenopausal women. Postmenopausal desire, tissue comfort, hormones, medications, sleep, and relationship context deserve their own assessment.
Is nasal spray as effective as injection?
That head-to-head clinical comparison has not been established.
Can PT-141 be used with Addyi?
Do not combine sexual-health medications without explicit instructions. Different mechanisms do not establish safety or benefit of the combination.
Can it be used with alcohol?
Alcohol can affect blood pressure, nausea, judgment, and sexual response. Product-specific guidance should govern rather than forum rules.
What if the first use does nothing?
Do not increase the amount or repeat the dose. Check whether the prescribed timing and technique were followed, whether nausea obscured the response, and whether desire was the correct symptom target. Ask how many attempts make a fair assessment and when persistent nonresponse means stopping.
What should improvement feel like?
The pivotal evidence points to desire and distress, not one mandatory sensation. Improvement can mean sexual interest appears more often or the absence of desire feels less distressing. It should not be judged solely by lubrication, intercourse, or orgasm, which are influenced by additional physical and contextual factors.
Bottom line
PT-141 has a strong, specific human story: bremelanotide injection improved desire and reduced distress in premenopausal women with acquired, generalized HSDD over 24 weeks. Vyleesi wins evidence, Rebody nasal spray wins needle-free simplicity, and troche wins when nasal delivery is the obstacle. Start with desire and distress; address pain, lubrication, hormones, orgasm, and relationship concerns in their own lanes.
Keep reading
- As-Needed Libido Medication Formats for Women
- Bremelanotide Options for Women With Distressing Low Desire
- Needle-Free Intimacy Treatments for Women: Sprays and Troches